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Background
Health care workers (HCW) who have been on the
front-line of the pandemic, highly exposed to SARS-
CoV-2 and frequently infected, are now the focus of re-
search on the longer-term evolution of COVID-19. This
is important as HCWs are generally young, previously
healthy adults and are representative of the active “work-
force” in countries worldwide. An infection with SARS-
CoV-2 can be seen as a twin-edged sword: on one hand,
having had the infection will confer some immunity or
protection against re-infection whilst on the other hand,
infection sequelae may result in subtle or significant
health consequences. How long will the infection -con-
ferred, antibody reactivity to the receptor-binding do-
main of SARS-CoV-2, the neutralising activity and the
specific memory B cells last post infection? Mounting
evidence suggests that this protection may last for 12
months or longer [1]. What is the price of this COVID
armour? The cost is steep!
SARS-CoV-2 infected individuals may experience de-
bilitating sequelae that persist for months and longer. A
systematic review on long-term sequelae in previously
healthy, young people aged < 50 years old found a broad
spectrum of symptoms [2]. These included persistent fa-
tigue, breathlessness, diminished quality of life, impaired
pulmonary function, myocarditis, neurological and
psychiatric diagnoses, slow and stagnant recovery of ol-
factory and gustatory function. Due to the global prolif-
eration of COVID-19 infection, the burden of sequelae
is thus projected to be immense.
Long-lasting immunity after COVID-19 in health
care workers
In this edition of BMC Medicine, three papers are pre-
sented showing a one-year follow up after COVID-19.
Dobaño et al. [3] followed up a cohort of 173 Spanish
health care workers one year after COVID-19. More
than 90% remained seropositive and only four re-
infections were reported. This suggests a long-lasting
immunity, that is protective, with respect to re-infection
for the vast majority of convalescents; however, the few
low- or non-responders seem to be at risk for a second
symptomatic infection with COVID-19. These findings
are reassuring but also raise the question as to whether a
year or more, post-infection, will the neutralising activity
also work as well against the Variants of Concern (VoCs)
as against the wild-type SARS-CoV-2 virus? A recent
analysis showed that people who were SARS-CoV-2 in-
fected and vaccinated had higher plasma antibodies and
nearly a fiftyfold increase in neutralising activity com-
pared to those who were previously infected but unvac-
cinated [1]. This has major implications for HCW who
have been infected during the earlier phase of the pan-
demic and who may now be exposed to variants for con-
cern. Vaccinate post infection!
Long-COVID in health care workers
Besides long-lasting immunity, COVID-19 also leads to
long-lasting sequelae, now termed long-COVID [2].
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Xiong et al. [4] follow up a cohort of 333 health care
workers (HCW) with severe COVID-19 and a median
age of only 36 years after 5, 8, and 11months. Import-
antly, nearly one third of these showed persistent symp-
toms of long-COVID 1 year after COVID-19 with a
decline in muscular strength, flexibility as well as agility
and dynamic balance. Similar results have been reported
one month after COVID-19 in a cohort of young Swiss
soldiers [5]. The authors of this study also reported de-
tectable antibody titers in more than 90% of the infected
one year after COVID-19. Importantly, inflammatory cy-
tokines such as TNF-alpha or IL-6 were measured in
this cohort and seem to decay slowly. The authors report
an increase in IgM titers, which could be indicative of
(continuous?) re-infection of HCW, although more data
are needed to answer this question.
Long-lasting functional and structural lung
changes after COVID-19
Chen et al. [6] followed up a cohort of 41 patients post
COVID-19 with a median age of 51 years using repetitive
CT imaging and lung function testing. 47% showed re-
sidual chest CT changes one year after discharge with
age being the main risk factor for such residual changes.
After six months, one third of the patients had
remaining changes in the lung CT (ground-glass opaci-
ties and reticular pattern) and one fifth of the patients
had an abnormal CO-Diffusion or total lung capacity of
more than a year after COVID-19. These observations
are compatible with a fibrotic process in the lung but
are no definitive proof thereof, since no biopsies were
performed. The authors nicely show the dynamics of CT
graphic changes with a peak three weeks after onset of
symptoms and a slow decline over the following months.
Conclusions
Larger, systematic studies quantifying overt and subtle
COVID sequelae based on objective criteria as well as
assessing the persistence and robustness of immunity
are needed. Such studies should ideally include a
COVID-19 naive control group as well as asymptomati-
cally infected and symptomatic COVID-19 convales-
cents. Because “long-COVID” is projected to impact
several body systems, test batteries must be comprehen-
sive, quantitative and sensitive enough to detect subtle
differences between such groups and to adequately de-
fine the disability associated with sequelae of the infec-
tion. With projected millions of “long haulers” in the
workforce, investigators will need to consider using non-
invasive testing, organ damage biomarkers and sample
biobanking to elucidate the extent of the post-pandemic
impact of COVID-19 and define the burden of long-
COVID. Such studies are already in progress [7] and
may detect hitherto unknown, long-term sequelae, and
give insight into the pathophysiology and consequences
of SARS-CoV-2 infection. Such data are urgently needed
to prepare for the societal impact of COVID-related
workforce disability and to develop strategies to mitigate
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